Table 2.
Characteristics of the Patients for Validation Cohort
| Total (n = 110) | DILI (n = 34) | AIH (n = 67) | Undetermined (n = 9) | |
|---|---|---|---|---|
| Sex (M:F) | 29:81 | 17:17 | 9:58 | 3:6 |
| Age (Years-old) | 60 (47–68) | 54 (47–64) | 61 (51–69) | 55 (38–66) |
| Prognosis | ||||
| Survival:Deceased:Transplantation | 105:1:4 | 64:1:2 | 39:2:1 | 9:0:0 |
| Daily alcohol intake | ||||
| <25 g, 25–60 g, 60g< | 100:8:2 | 26:6:2 | 66:1:0 | 8:1:0 |
| WBC (/μL) | 5645 (4415–7793) | 6685 (5380–9243) | 5270 (4300–6545) | 6550 (4490–6850)b |
| Platelet (103/μLa) | 19.8 (15.0–24.5) | 21.0 (14.4–25.6) | 19.3 (15.7–24.1) | 19.0 (16.7–24.5) |
| Alb (mg/dL) | 3.6 (3.1–4.0) | 3.8 (3.3–4.1) | 3.5 (3.1–4.0) | 3.5 (3.2–3.8) |
| Cre (mg/dL) | 0.63 (0.53–0.81) | 0.80 (0.61–1.03) | 0.60 (0.52–0.66) | 0.63 (0.51–0.89) |
| AST (U/L) | 545 (328–933) | 496 (275–849) | 736 (434–1149) | 388 (275–514) |
| ALT (U/L) | 641 (424–1085) | 658 (429–1041) | 707 (558–1210) | 516 (390–978) |
| ALP (U/L) | 505 (364–734) | 484 (357–842) | 595 (400–764) | 453 (302–521) |
| T-Bil (mg/dL) | 4.6 (1.6–11.0) | 2.9 (1.2–14.7) | 6.2 (2.4–11.6) | 6.3 (2.3–7.9) |
| D-Bil (mg/dL) | 2.9 (0.7–8.9) | 1.8 (0.5–11.5) | 4.7 (1.6–9.9) | 4.0 (0.7–6.0) |
| IgG (mg/dL) | 1590 (1270–2119) | 1416 (1154–1595) | 1785 (1457–2305) | 1191 (1066–1300)a,b |
| IgM (mg/dL) | 115 (79–181) | 96 (67–149) | 113 (87–213) | 140 (102–165) |
AIH, autoimmune hepatitis; Alb, Albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cre, creatinine; D-Bil, direct bilirubin; DILI, drug-induced liver injury; Ig, immunoglobulin; PT-INR, prothrombin time international ratio; T-Bil, total bilirubin; WBC, white blood cell.
a
P < .05, AIH, vs Undetermined cause.
b
P<.05, AIH, vs DILI.